This statistic functions tool runs Linear Regression Intercept function and companion studies for Silence Therapeutics. Signals here center on statistical functions describing dispersion and variability alongside volatility and performance references.Provide Time Period to run the technical study.
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Linear Regression Intercept is the expected mean value of Silence Therapeutics PLC price seriese where values of its benchmark or peer price series are zero.
Silence Therapeutics Technical Analysis Modules
Most technical analysis of Silence Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Silence from various momentum indicators to cycle indicators. When you analyze Silence charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Silence Therapeutics PLC is scheduled to announce its earnings this week.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. Silence Therapeutics is traded on NASDAQ Exchange in the United States. This overview emphasizes how Silence Therapeutics compares to peers on valuation quality and operating consistency. Current metrics include P/B of 3.99. Silence Therapeutics has market cap of 296.16 M, ROE of -90.27%.
Methodology
Unless otherwise specified, financial data for Silence Therapeutics PLC is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Silence (USA Stocks:SLN) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Silence Therapeutics PLC may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Be your own money manager
Tracking Silence Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A comprehensive view of Silence Therapeutics PLC starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Silence Therapeutics PLC Stock. Key reports that frame Silence Therapeutics PLC Stock are listed below:
Silence Therapeutics has market cap of 296.16 M, operating margin of -371.5%, ROE of -90.27%. Review World Market Map for broader portfolio context. This reflects a position in Silence Therapeutics PLC in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Analysis related to Silence Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Earnings Share
-1.35
Revenue Per Share
0.012
Quarterly Revenue Growth
-1.00
Return On Assets
-0.31
Return On Equity
-0.90
Silence Therapeutics PLC market price can diverge from book value, the accounting figure shown on Silence balance sheet. Silence Therapeutics' market capitalization is 296.16 M. With a P/B ratio of 3.99, the market values Silence Therapeutics well above its book equity. Enterprise value stands at 181.39 M. Intrinsic value is an analytical estimate of Silence Therapeutics' underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
It is useful to distinguish Silence Therapeutics' value from its trading price, which are computed with different methods. For Silence Therapeutics, key inputs include a P/B ratio of 3.99, ROE of -90.27%, and revenue of 559 K. By contrast, market price reflects the level where buyers and sellers transact.